An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
← catalyst calendarNCT03844048 · readout ≤ 377 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
165actual
Sites
56
Countries
Australia, Austria, Belgium +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-09-06 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2019-02-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Multiple Myeloma
- Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia
- Cancer
Intervention
- Drug: Venetoclax — also filed as ABT-199, Venclexta
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Adverse Events
measured From first dose of study drug until 30 days following last dose of study drug (up to approximately 5 years).
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed